Amicus Therapeutics v. Aurobindo Pharma: Migalastat ANDA Consent Judgment
Amicus Therapeutics filed an ANDA patent infringement action against Aurobindo Pharma over three patents protecting GALAFOLD (migalastat), a treatment for Fabry disease. The case resolved after 557 days via a consent judgment in which Aurobindo acknowledged validity, enforceability, and infringement, and accepted a permanent injunction subject to a separate licence agreement.
Hatch-Waxman ANDA battle over rare-disease drug ends in Amicus victory
Amicus Therapeutics US, LLC and Amicus Therapeutics, Inc. filed suit on 13 June 2024 in the District of Delaware against Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc., asserting U.S. Patent Nos. 11,633,388; 11,833,164; and 12,042,490. The trigger was Aurobindo’s ANDA No. 217786, filed with the FDA seeking approval to commercially manufacture and sell a generic version of migalastat — the active ingredient in Amicus’s GALAFOLD 123 mg capsules, indicated for Fabry disease.
The case closed on 22 December 2025 via a consent judgment and permanent injunction entered by Judge Christopher J. Burke. Under the order, Aurobindo expressly acknowledged Amicus’s ownership and standing, conceded the validity and enforceability of all three asserted patents, and admitted infringement under 35 U.S.C. § 271(e)(2). Aurobindo and its successors are permanently enjoined from manufacturing, selling, or distributing any generic migalastat product covered by its ANDA, except pursuant to a separate licence agreement simultaneously executed with the consent judgment. All claims were dismissed without prejudice.
At 557 days, the resolution sits near the outer edge of the standard Hatch-Waxman 30-month litigation window, consistent with parties negotiating a commercial licence arrangement before trial. The simultaneous execution of a licence agreement alongside the injunction strongly suggests Aurobindo secured a future market-entry date — a common settlement structure in rare-disease ANDA cases. The financial terms of the licence and any authorised generic rights remain confidential and are not discernible from the public record.
Filing to Consent Judgment in 557 days
557 days — longer than the typical Hatch-Waxman 30-month stay, suggesting negotiated resolution beyond automatic stay expiry
Consent judgment and permanent injunction: what the resolution means for both parties
Consent judgment is a court order, not just a settlement agreement
A consent judgment is a judicially enforceable decree entered by the court with the parties’ agreement. Unlike a private settlement, it carries the full coercive authority of a court order. Here, the consent judgment also constitutes a ‘consent decree’ under 21 U.S.C. § 355(j)(5)(B)(iii), directly affecting when the FDA may grant final approval of Aurobindo’s ANDA — giving the order regulatory as well as legal effect.
Court-ordered resolutionAmicus secures acknowledgment of validity and a permanent injunction
Aurobindo’s express concession that all three asserted patents are valid, enforceable, and infringed is a significant public record win for Amicus. The permanent injunction blocks unlicensed generic migalastat entry indefinitely. Critically, the simultaneous licence agreement preserves Amicus’s ability to control market timing and terms for any future generic entry, protecting GALAFOLD’s commercial exclusivity window while creating a monetisation vehicle.
Patents upheld + injunction grantedAurobindo accepts infringement but likely secures future licensed entry
Aurobindo’s infringement acknowledgment forecloses any immediate unlicensed generic launch. However, the existence of a separate licence agreement — executed simultaneously with the injunction — is consistent with Aurobindo negotiating an authorised entry date tied to patent expiry or a specified future trigger. The ‘without prejudice’ dismissal of all claims and the absence of fee-shifting suggest a commercially balanced outcome rather than an outright defeat for Aurobindo.
Injunction accepted, licence securedGALAFOLD’s exclusivity reinforced across a three-patent portfolio
For the rare-disease pharma sector, this outcome demonstrates the enforcement strength of layered patent portfolios in Hatch-Waxman litigation. Three patents covering migalastat — each separately asserted and acknowledged valid — creates a compounding barrier to generic entry. Other ANDA filers for migalastat or comparable pharmacological chaperones for lysosomal storage disorders face a substantially higher challenge bar following Aurobindo’s public validity concession.
Rare-disease IP exclusivity strengthenedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Amicus Therapeutics US, LLC | Company | Rare-disease biopharmaceutical company — holder of US11633388, US11833164, and US12042490Search in Eureka ↗ |
| Co-Plaintiff | Amicus Therapeutics, Inc. | Company | Search in Eureka ↗ |
| Defendant | Aurobindo Pharma, Ltd. | Company | Indian generic pharmaceutical manufacturer and its US subsidiary seeking ANDA approval for generic migalastatSearch in Eureka ↗ |
| Co-Defendant | Aurobindo Pharma USA, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Chad S.C. Stover | Attorney | Counsel for Amicus Therapeutics US, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Barnes & Thornburg, LLP | Law Firm | Representing Amicus Therapeutics US, LLCSearch in Eureka ↗ |
| Defendant counsel | R. Touhey Myer. | Attorney | Counsel for Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Defendant law firm | Kratz & Barry LLP | Law Firm | Representing Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Christopher J. Burke | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent judgment is notable for the breadth of Aurobindo’s concessions: validity, enforceability, and infringement of all three asserted patents are explicitly acknowledged on the record. The ‘without prejudice’ dismissal of claims is procedurally standard in consent judgment structures and does not diminish the injunctive relief obtained. The court’s retention of jurisdiction over both the injunction and the separate licence agreement ensures ongoing enforceability — an important protection for Amicus if Aurobindo’s commercial conduct later implicates either instrument.
US11833164B2 — Migalastat formulations for Fabry disease treatment
U.S. Patent No. 11,833,164 (application no. US16/987884) is one of three patents Amicus asserted to protect GALAFOLD (migalastat 123 mg free base capsules), the first oral monotherapy approved for Fabry disease in patients with amenable GLA mutations. Migalastat is a pharmacological chaperone — a small molecule that stabilises misfolded alpha-galactosidase A enzyme variants, enabling proper lysosomal trafficking. Patent protection in this class of rare metabolic disorder therapeutics typically covers formulation, dosing regimen, and method-of-treatment claims.
For the pharmaceutical sector, the three-patent portfolio surrounding migalastat signals Amicus’s layered exclusivity strategy for its sole approved oral Fabry therapy. With GALAFOLD generating significant annual revenues and no currently approved generic equivalent, the commercial value of maintaining injunctive protection through patent expiry is substantial. Competitors developing pharmacological chaperones for other lysosomal storage disorders should treat this portfolio as a benchmark for claim scope and enforcement posture in rare metabolic disease therapeutics.
Should you run an FTO against the migalastat patent portfolio?
Any company developing oral pharmacological chaperone therapies for Fabry disease or related lysosomal storage disorders — or formulating migalastat-based products — should conduct a freedom-to-operate analysis against US11633388, US11833164B2, and US12042490 before advancing to clinical or regulatory stages. The public validity concession by Aurobindo strengthens the presumption of enforceability across all three patents and removes a key prior-art challenge data point from the public record.
PatSnap Eureka’s FTO Search Agent can map your compound, formulation, or dosing method claims against the full Amicus migalastat portfolio, identify claim-by-claim overlap, and surface related continuation applications that may extend exclusivity beyond the three asserted patents. Eureka’s prior art mining tools can also identify prosecution history estoppel arguments and claim differentiation opportunities if your development programme requires designing around this portfolio.
Run a freedom-to-operate analysis on US11833164B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman ANDA patent cases in Delaware District Court
Explore comparable ANDA infringement actions involving rare-disease small-molecule drugs resolved by consent judgment in the District of Delaware.
What this case signals for the rare-disease pharma IP landscape
The Amicus–Aurobindo consent judgment offers a clear read on how multi-patent ANDA strategies play out in Delaware for rare-disease biologics.
Multi-patent ANDA portfolios create compounding leverage in negotiations
Amicus asserted three patents simultaneously, forcing Aurobindo to contest validity and enforceability across all three to mount any defence. This stacking strategy — common in rare-disease Hatch-Waxman cases — significantly raises the cost and risk of litigation for generic challengers and typically accelerates settlement on originator-favourable terms.
Consent decrees with licences are the dominant rare-disease Hatch-Waxman exit
The simultaneous consent judgment and licence agreement structure seen here is the standard commercial resolution in rare-disease ANDA disputes. It allows originators to preserve injunctive protection while monetising future generic entry, and gives generics a defined market pathway — avoiding the binary risk of a full trial verdict that could invalidate or uphold patents absolutely.
Amicus v Aurobindo — key questions answered
Aurobindo expressly acknowledged Amicus’s ownership and standing, admitted that U.S. Patent Nos. 11,633,388; 11,833,164; and 12,042,490 are valid and enforceable, and conceded infringement under 35 U.S.C. § 271(e)(2). These concessions are on the public court record as part of the consent judgment entered 22 December 2025.
The permanent injunction prohibits Aurobindo and its successors, assigns, and affiliates from manufacturing, using, selling, offering for sale, importing, or distributing any generic migalastat product covered by ANDA No. 217786, except pursuant to a licence granted by Amicus or an exemption under 35 U.S.C. § 271(e)(1). The injunction took effect on the date of entry of the consent judgment.
No. Dismissal without prejudice in a consent judgment context is a standard procedural mechanism for closing the case docket. The substantive protections — permanent injunction and Aurobindo’s validity and infringement concessions — remain in full force. The court also retained jurisdiction to enforce both the consent judgment and the separate licence agreement.
The consent judgment explicitly invokes 21 U.S.C. § 355(j)(5)(B)(iii)(I)(bb), designating it a formal ‘consent decree’ for Hatch-Waxman purposes. This means final FDA approval of ANDA No. 217786 may be granted on the date the consent judgment is entered — but any actual launch by Aurobindo remains subject to the permanent injunction and the terms of the separate licence agreement.
Aurobindo’s public concession of validity and enforceability of all three asserted patents creates persuasive — though not formally binding — precedent that other ANDA challengers will face in Delaware litigation. Any paragraph IV certifier must contend with this record, raising the litigation cost and risk of a subsequent challenge. The three-patent portfolio structure also means challengers must overcome multiple independently valid patents to achieve an unlicensed generic launch.
PatSnap Eureka searches patents and litigation data to answer instantly.